Evidence-based update on rosacea comorbidities and their common physiologic pathways - 13/12/17
![](/templates/common/images/mail.png)
Abstract |
Rosacea is a common chronic inflammatory disease affecting the facial skin whose etiology and pathophysiology are the subject of much investigation. Risk factors include genetic and environmental elements that may predispose individuals to localized inflammation and abnormal neurovascular responses to stimuli. Recent studies have introduced an array of systemic rosacea comorbidities, such as inflammatory bowel disease and neurologic conditions, that can be challenging to synthesize. We critically review the current data behind reported rosacea comorbidities and identify and highlight underrecognized physiologic mediators shared among rosacea and associated comorbidities. This information may be helpful in addressing patient questions about potential systemic implications of rosacea and can serve as a candidate platform for future research to understand rosacea and improve treatments.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular, comorbidity, environment, gastrointestinal, genetics, immune, microbiome, neurologic, pathophysiology, rosacea
Abbreviations used : CeD, CVD, GST, GWAS, HLA, HR, IBD, IL, MHC, MS, OR, RA, ROS, SIBO, UC
Plan
Funding sources: None. |
|
Dr Holmes is an employee of Galderma Laboratories, L.P., Dr Spoendlin received an independent research grant funded by Galderma as a PhD student at the University of Basel between 2010-2013, Dr Baldwin is a speaker and advisor for Galderma, and Dr Chang has been a clinical investigator for studies sponsored by Galderma. Dr Chien does not have conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 78 - N° 1
P. 156-166 - janvier 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?